A Phase III, randomized, double-blind, placebo-controlled multi-country study to demonstrate efficacy of a single dose of unadjuvanted RSV Maternal vaccine, administered IM to pregnant women 18 to 49 years of age, for prevention of RSV associated LRTI in their infants up to 6 months of age

  • Buttery, Jim (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date25/03/21 → 24/03/26

Keywords

  • phase 3 study
  • treatment efficacy
  • treatment safety
  • vaccine
  • RSV maternal vaccine